Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers. evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone marrow (BM) environment. the primary leukemia site. https://wholesfoodsboxs.shop/product-category/pulses/